Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
STAT2h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck narrows outlook; Keytruda drives Q3 beat despite Gardasil impact
Merck (NYSE:MRK) beat Street forecasts with its Q3 2024 revenue on Thursday as its blockbuster cancer therapy Keytruda continued to drive sales growth while its human papillomavirus vaccine franchise, ...
Investing14d
Merck earnings top estimates amid solid demand for Keytruda cancer drug
Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...
NBC New York14d
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV ...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.